Abstract
Parkinson's disease (PD) is a common neurodegenerative disorder characterized by loss of dopaminergic neurons in substantia nigra region and the presence of α-synuclein aggregates in the striatum and surrounding areas of brain. Evidences suggest that neuroinflammation plays a role in the progression of PD. We examined the neuro-protective effects of Bacopa monnieri (BM) in regulating neuroinflammation. Administration of BM suppressed the level of pro-inflammatory cytokines, decreased the levels of α-synuclein, and reduced reactive oxygen species (ROS) generation in PD animal model. Pre-treatment of BM showed more prominent results as compare to co- and post-treatment. Results suggest that Bacopa can limit inflammation in the different areas of brain, thus, offers a promising source of novel therapeutics for the treatment of many CNS disorders.
Keywords:
Bacopa monnieri; Cytokines; Neurodegeneration; Parkinson’s disease; ROS.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Bacopa*
-
Cerebral Cortex / drug effects
-
Cerebral Cortex / metabolism
-
Chemokine CCL4 / metabolism
-
Disease Models, Animal
-
Hippocampus / drug effects
-
Hippocampus / metabolism
-
Interleukin-1beta / metabolism
-
Interleukin-6 / metabolism
-
Male
-
Neuroprotective Agents / pharmacology
-
Neuroprotective Agents / therapeutic use*
-
Oxidative Stress / drug effects*
-
Parkinson Disease, Secondary / chemically induced
-
Parkinson Disease, Secondary / drug therapy*
-
Parkinson Disease, Secondary / metabolism
-
Plant Extracts / pharmacology
-
Plant Extracts / therapeutic use*
-
Rats
-
Rats, Wistar
-
Reactive Oxygen Species / metabolism
-
Rotenone
-
Substantia Nigra / drug effects
-
Substantia Nigra / metabolism
-
Tumor Necrosis Factor-alpha / metabolism
-
alpha-Synuclein / metabolism
Substances
-
Chemokine CCL4
-
Interleukin-1beta
-
Interleukin-6
-
Neuroprotective Agents
-
Plant Extracts
-
Reactive Oxygen Species
-
Tumor Necrosis Factor-alpha
-
alpha-Synuclein
-
Rotenone